Inhance 3D Velocity depicts colorcodedarterial and venous flow inbrain without administration ofcontrast media.
Inhance 3D Velocity depicts colorcoded arterial and venous flow in brain without administration of contrast media. Phase-contrast sequence, optimized to run on GE Healthcare’s high-end 3T Discovery MR750 and 1.5T Discovery MR450, is especially suited for use in patients who may be susceptible to gadolinium- linked nephrogenic systemic fibrosis. (Provided by GE Healthcare)
Can AI Assessment of PET Imaging Predict Treatment Outcomes for Patients with Lymphoma?
June 2nd 2025The use of adjunctive AI software with pre-treatment PET imaging demonstrated over a fourfold higher likelihood of predicting progression-free survival (PFS) in patients being treated for lymphoma, according to a new meta-analysis.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
ASCO: Study Reveals Significant Racial/Ethnic Disparities with PSMA PET Use for Patients with mPCa
May 30th 2025Latinx patients with metastatic prostate cancer were 63 percent less likely than non-Hispanic White patients to have PSMA PET scans, according to a study of 550 patients presented at the American Society of Clinical Oncology (ASCO) conference.